PTGS2 and cancer: Hence, the use of COX-2-specific inhibitors, a subclass of nonsteroidal anti-inflammatory drugs (NSAIDs), and nonspecific COX-2 inhibitors such as aspirin reduce the cancer risk, potentiate antiangiogenic cancer therapy, and reduce metastasis in cancer patients [101,103].